Abstract: A method for the prophylaxis and treatment of MOF using certain angiotensin II type 1 receptor antagonists and a pharmaceutical preparation comprising these compounds.

Abstract: The use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate, chondroitinsulphates and dextran sulphate for the manufacture of an agent capable of providing stimulated regeneration of hard tissue;a process for stimulating regeneration of hard tissue in connection with so called osseointegration; andimplant intended for integration into hard tissue, particularly bone tissue.

Abstract: The invention concerns compounds of formula I ##STR1## in which R.sub.1 is hydrogen or a straight or branched hydrocarbon chain; R.sub.2 is hydrogen or a straight or branched hydrocarbon chain; R.sub.3 is acyl; X.sub.1 is hydrogen, fluorine or chlorine; and X.sub.2 is hydrogen, fluorine or chlorine. Also disclosed are processes for preparation of the compounds, pharmaceutical compositions containing them and methods employing the compounds in the treatment of inflammatory and allergic conditions.

Abstract: In a method for measuring a dose of a drug inhaled by an animal, the momentary concentration of the drug in an aerosol supplied to the animal and the momentary inhalation flow rate of the animal are determined. An inhaled partial dose is calculated from each determined inhalation flow rate value and a corresponding concentration value. The calculated inhaled partial doses are added to obtain the total dose inhaled by the animal.

Abstract: The present invention relates to novel quinoline derivatives of the formula ##STR1## which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

Abstract: New 3,3'-dithiobis(propionic acids) and esters thereof with immunomodulating effect, processes for their preparation, pharmaceutical compositions containing them and methods of their pharmacological use.

Abstract: Guanidine derivatives of formula I ##STR1## wherein R.sup.8 represents hydrogen, halogen, alkyl C1 to 6, nitro, trifluoromethyl, thioalkyl C1 to 6, hydroxy, alkoxy C1 to 6, or a group selected from --NR.sup.4 R.sup.5, --O(CH.sub.2).sub.p Q, --(CH.sub.2).sub.m OQ, --(CH.sub.2).sub.m NR.sup.1 R.sup.2, --O(CH.sub.2).sub.m NR.sup.1 R.sup.2, --NHCO(CH.sub.2).sub.m NH(CH.sub.2).sub.n Q or --(CH.sub.2).sub.p CONR.sup.1 R.sup.2, or R.sup.8 represents the group A--CO--B; R.sup.9 represents hydrogen, halogen, alkyl C1 to 6, nitro or trifluoromethyl;and R.sup.1, R.sup.2, R.sup.4, R.sup.5, n, m, p, Q, A, B, and W are as defined in the specification, are described together with processes for their manufacture and compositions containing them. Compounds of formula I are useful in therapy.

Abstract: The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA, of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and selected from H and alkyl; X and Y are the same or different and selected from alkoxy, aryloxy, alkyl, alkylthio, arylthio, fluoroalkyl, halogen, cyano, OCF.sub.3 and SCF.sub.3 with the proviso that the compound of formula I wherein R.sub.1 and R.sup.2 =H, X=Br and Y=Me is excluded;or a pharmaceutically acceptable salt thereof, methods and intermediates for their preparation, novel pharmaceutical compositions and the use thereof for inhibiting the enzyme 3-hydroxyanthranilate oxygenase, 3-HAO, responsible for the production of the endogenous neurotoxin quinolinic acid, QUIN.

Abstract: Valve intended to be used in particular in inhalation devices having a body, such as a spacer, the valve having a housing comprising an first part which is adapted to be mounted on an outlet opening of the body of the inhalation device, a second part on to which a mouthpiece or a face mask can be mounted, said first and second parts being provided with a first bore defining an inhalation channel, a first membrane provided in the inhalation channel and a second membrane, wherein the second part is provided with a second bore, said second bore defining the exhalation channel, the two channels being provided separated from one another and placed adjacent each other.

Abstract: A method for the treatment of restenosis using certain cystine derivatives and a pharmaceutical preparation comprising these derivatives.

Abstract: A method for treatment of gastric acid related diseases by inhibition of gastric acid secretion comprising administering to a mammal in need of treatment a therapeutically effective amount of the (-)-enantiomer of 5-methoxy-2-??(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H-benz imidazole or a pharmaceutically acceptable salt thereof, so as to effect decreased interindividual variation in plasma levels upon administration. The use of the (-)-enantiomer of omeprazole to receive increased average plasma levels (AUC) upon administration of the same doses of the (-)-enantiomer of omeprazole compared to those of racemic omeprazole is also claimed, as well as an improved antisecretory effect and a better clinical effect.

Abstract: There are described finely divided particles of a pharmaceutical substance, wherein the substance when submitted to water vapor gives off heat of less than 1.2 Joules per gram, processes for their production and pharmaceutical formulations containing them.

Abstract: The invention relates to a device for filling with high accuracy a finely divided powdered medicament having a particle size smaller than 10 .mu.m into cavities having a size corresponding to the volume of powder to be filled, wherein said device comprises oscillating and rotating means for breaking down aggregates formed in the finely divided powdered medicament and filling and for compacting it in said cavities. The invention also includes a method of filling with high accuracy of a finely divided powdered medicament having a particle size smaller than 10 .mu.m and to fill said finely divided powdered medicament into cavities, wherein the finely divided powdered medicament is transported and compacted in said cavities by oscillating and rotating means.

Abstract: Compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, chloro, bromo, nitro, cyano, trifluoromethyl, and R.sub.3 and R.sub.4 are independently selected from straight or branched lower (1-5 carbon atoms) alkyl groups, and including all optical isomers, provided that when R.sub.3 is methyl and R.sub.4 is tert.-butyl, then R.sub.1 /R.sub.2 are not hydrogen/hydrogen, hydrogen/2'-trifluormethyl, 2'-chloro/3'-chloro, and when R.sub.3 is methyl and R.sub.1 /R.sub.2 is hydrogen/3'-nitro, then R.sub.4 are not methyl, ethyl, propyl, iso-propyl, tert.-butyl, processes for their preparation, pharmaceutical preparations containing them and the use of the compounds in lowering the blood pressure.

Abstract: The invention relates to compounds of the formulaA.sup.1 --A.sup.2 --NH--(CH.sub.2).sub.n --B Formula IandA.sup.1 --A.sup.2 --NH--(CH.sub.2).sub.n --B--D Formula Vas well as stereoisomers and physiologically acceptable salts thereof which act as competitive inhibitors of trypsin-like serine proteases, particularly kininogenases. The invention further relates to pharmaceutical compositions containing the compounds as active ingredients and the use of the compounds as kininogenase inhibitors and in the treatment of diseases related to kinin formation.

Abstract: A process for manufacturing a catheter for insertion into a body cavity, for instance a catheter used for insertion into the urethra. The catheter has a tip portion provided with one or several drainage or flushing openings adjacent to the free end which is to be inserted into the body cavity. The outside of the catheter is provided with a coating. The process includes injection-molding a separate tip portion of the catheter. The tip portion includes an inner lumen and the drainage/flushing openings. The inner and outer diameters of the tip correspond to those of a standard tube. An end of a standard tube and an end of the tip portion are formed to conform to each other. These formed ends are then joined in a joining operation. The coating is applied to the standard tube before the joining operation is performed.

Abstract: Angiotensin-II antagonists of the formula ##STR1## wherein R.sub.1 is, other than hydrogen and, inter alia, halogen, lower alkyl or cycloalkyl; R.sub.2 is, inter alia, optionally substituted benzimidazol-2-yl, 5,6,7,8-tetrahydro-imidazo?1,2-a!pyridin-2-yl, butanesultam-1-yl, imidazol-4-yl, and tetrahydobenzimidazol-2-yl; R.sub.3 is, inter alia, lower alkyl; and, R.sub.4 is an acidic group, such as carboxyl or tetrazolyl. An exemplary compound is: 4'-?(2-ethyl-4-methyl-6-(5,6,7,8-tetrahydroimidazo?1,2-a!pyridin-2-yl)-ben zimidazol-1-yl)-methyl!-biphenyl-2-carboxylic acid.

Abstract: The present invention relates to novel heterocyclic compounds having the general formula (1) ##STR1## wherein: X.sub.1 and X.sub.2 are independently O, S or Se;Y.sub.1 and Y.sub.2 are independently C or N with the proviso that at least one of Y.sub.1 and Y.sub.2 is N;Y.sub.3 and Y.sub.4 are independently C or N with the proviso that at least one of Y.sub.3 and Y.sub.4 is N;R.sub.1 and R.sub.2 each represent one or more groups independently selected from H, lower alkyl, lower alkoxy-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl or CF.sub.3 ;and A is ##STR2## geometrical and optical isomers and racemates thereof where such isomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof;having therapeutic activity, processes and intermediates for their preparation, pharmaceutical formulations containing said compounds and the medicinal use of said compounds.